OLMA

Olema Pharmaceuticals, Inc. [OLMA] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

OLMA Stock Summary

Top 10 Correlated ETFs

OLMA

Top 10 Correlated Stocks

OLMA

In the News

OLMA Financial details

Company Rating
-
Market Cap
607.23M
Income
-95.34M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
74
Optionable
No
Shortable
Yes
Earnings
07 May 2024
P/E
-5.73
Forward P/E
-
PEG
3.41
P/S
-
P/B
1.95
P/C
-
P/FCF
-7.67
Quick Ratio
17.39
Current Ratio
17.66
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.13
EPS next Y
-
EPS next Q
-
EPS this Y
-16.41%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
2.08%
-
-
-
-
SMA20
-12.68%
SMA50
-9.61%
SMA100
195.96%
Inst Own
-
Inst Trans
-
ROA
-32%
ROE
-46%
ROC
-0.37%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.55-17.791
52W High
+33.06%
52W Low
+654%
RSI
36.79
Rel Volume
1.18
Avg Volume
811K
Volume
955.93K
Perf Week
-9.56%
Perf Month
-10.52%
Perf Quarter
304.65%
Perf Half Y
292.71%
-
-
-
-
Beta
2.106
-
-
Volatility
0.99%, 1.68%
Prev Close
0.13%
Price
22.62
Change
-4.4%

Something similar

Top by Market Cap
3V64.DE
MSFT
DHR-PB
LLY.DE
FB2A.DE
Top Correlated ETFs
GRN
HYLS
CNBS
UC84.L
IYC
Top Correlated Stocks
BBW
RICK
FIGS
QTRX
8158.HK
Similar Market Cap
1181.HK
RERE
TNXT.MI
BIEAX
NUMV

Company Profile

Healthcare Biotechnology
  • Volume Average 811K
  • Market Capitalization 607.23M
  • Employee 74
  • CEO Dr. Sean P. Bohen M.D., Ph.D.
  • Headquarters San Francisco,CA,US
  • IPO Date 2020-11-19
  • Website https://www.olema.com

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.